Want to see HK:2252 full AI Analyst Report?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Stock Price & Analysis
2252 Stock Chart & Stats
- Day’s Range
- HKD 20.52 - HKD 22.00
- 52-Week Range
- HKD 19.64 - HKD 35.34
- Previous Close
- HKD 21.18
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- HKD 21.97B
- Enterprise Value
- HKD 24.84B
- Total Cash (Recent Filing)
- HKD 640.42M
- Total Debt (Recent Filing)
- HKD 426.37M
- Price to Earnings (P/E)
- ―
- Beta
- 1.63
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- 0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Acceleration
The sharp acceleration in revenue indicates improving commercial traction for the company’s medical robotics business. If sustained, stronger system adoption can expand the installed base and create additional recurring demand for instruments, consumables, and services over the next several quarters.
Positive Gross Margin
A positive gross margin shows that the company retains economic value after direct product costs, providing a foundation for future operating leverage as sales scale. Continued revenue growth could allow fixed development and commercialization expenses to be absorbed more efficiently over time.
Lower Leverage
Meaningfully lower leverage reduces balance-sheet pressure relative to the prior year and may improve financial flexibility. A less debt-intensive capital structure can make it easier to fund commercialization and product development while reducing exposure to financing constraints.
Bears Say
Persistent Unprofitability
The company remains materially unprofitable, so revenue growth has not yet translated into sustainable earnings. A large net loss can limit internally funded investment, require continued external support, and make the durability of the business model dependent on achieving substantial operating leverage.
Negative Cash Generation
Recurring negative operating and free cash flow indicate that the business is not yet self-funding its operations. Continued cash burn can constrain investment in robotics platforms and commercialization, while increasing reliance on financing or other sources of capital to sustain growth.
Weak Returns And Capital Pressure
Deeply negative returns on equity show that the capital base is not currently generating acceptable profits and remains under pressure from ongoing losses. Declining equity can reduce financial resilience and leave less capacity to absorb setbacks while the company pursues expansion.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H News
2252 FAQ
What was Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price range in the past 12 months?
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap?
When is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date?
How were Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s earnings last quarter?
Is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H overvalued?
Does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H pay dividends?
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate?
How many shares outstanding does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H have?
What happened to Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Shanghai MicroPort MedBot (Group) Co., Ltd. Class H?
What is the TipRanks Smart Score and how is it calculated?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Stock Smart Score
Company Description
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive research, development, design, production, and distribution of surgical robotic systems, catering to markets in China and Europe. Their innovative product range features Toumai, a versatile laparoscopic surgical robot employed in urologic, gynecologic, thoracic, and general surgeries. They also provide DFVision, a 3D electronic laparoscope designed to improve visualization during abdominal, thoracic, and pelvic operations. For orthopedic procedures, the Honghu robot aids in knee and hip joint replacements, while the R-One system is specifically engineered for vascular interventions like coronary angioplasty. The iSR'obot, known as the Mona Lisa robotic system, specializes in transperineal prostate biopsies. Additionally, the company's offerings extend to specialized robots for spinal procedures, trans-bronchial diagnosis and treatment, TAVR (Transcatheter Aortic Valve Replacement), and automated needle-targeting systems for precise percutaneous lung biopsies and nephrolithotomy. Founded in 2014 and headquartered in Shanghai, China, the company functions as a subsidiary of MicroPort Scientific Corporation.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Chao He
- Employees
- 464
- Website
- www.medbotsurgical.com
- Address
- CN
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 6 | 10 |
| Technical Analysis | 2 | 5 | 1 |
| Moving Averages | 2 | 1 | 9 |









